Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

February 11, 2017

Conditions
Recurrent Uterine Corpus SarcomaUterine Corpus Leiomyosarcoma
Interventions
DRUG

Alisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (50)

10065

Memorial Sloan-Kettering Cancer Center, New York

19001

Abington Memorial Hospital, Abington

19611

Reading Hospital, West Reading

27104

Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

29621

AnMed Health Cancer Center, Anderson

32803

Florida Hospital Orlando, Orlando

39216

University of Mississippi Medical Center, Jackson

43214

Riverside Methodist Hospital, Columbus

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

46260

Saint Vincent Hospital and Health Care Center, Indianapolis

48060

Lake Huron Medical Center, Port Huron

48106

Michigan Cancer Research Consortium NCORP, Ann Arbor

48124

Beaumont Hospital-Dearborn, Dearborn

48154

Saint Mary Mercy Hospital, Livonia

48236

Saint John Hospital and Medical Center, Detroit

48341

Saint Joseph Mercy Oakland, Pontiac

48439

Genesys Regional Medical Center, Grand Blanc

48502

Hurley Medical Center, Flint

48601

Saint Mary's of Michigan, Saginaw

48912

Sparrow Hospital, Lansing

49201

Allegiance Health, Jackson

50010

McFarland Clinic PC-William R Bliss Cancer Center, Ames

50309

Iowa Methodist Medical Center, Des Moines

Iowa-Wide Oncology Research Coalition NCORP, Des Moines

Medical Oncology and Hematology Associates-Des Moines, Des Moines

50314

Medical Oncology and Hematology Associates-Laurel, Des Moines

Mercy Medical Center - Des Moines, Des Moines

50316

Iowa Lutheran Hospital, Des Moines

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

60521

Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

65804

Cancer Research for the Ozarks NCORP, Springfield

Mercy Hospital Springfield, Springfield

65807

CoxHealth South Hospital, Springfield

68114

Nebraska Methodist Hospital, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa

77030

Memorial Hermann Texas Medical Center, Houston

83706

Saint Alphonsus Cancer Care Center-Boise, Boise

96813

University of Hawaii Cancer Center, Honolulu

06102

Hartford Hospital, Hartford

06105

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

06050

The Hospital of Central Connecticut, New Britain

48106-0995

Saint Joseph Mercy Hospital, Ann Arbor

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT01637961 - Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | Biotech Hunter | Biotech Hunter